LifeSci Advisors provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. LifeSci Advisors increases client visibility within the investment community and educates investors on opportunities offered by these companies. Our core capabilities include non-deal roadshow planning and execution, KOL Events/R&D Days and financial communications. With a local presence in New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, LifeSci Advisors provides high quality service for clients with our intensive healthcare sector specialization. The LifeSci team has 350+ years of healthcare experience in sell-side research, institutional equity sales, capital markets/investment banking, institutional investing, VC investing and strategic IR advisory. We have long-standing relationships with key investors and senior professionals across the industry. Our healthcare expertise allows us to provide objective, unbiased advice to private and public biotech, specialty pharma, medical technology, diagnostics, and healthcare services companies.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer,
The Canton of Basel-Stadt contributes to the further development of convention-related tourism. Conventions are specifically acquired, developed and held, thus accessing a potential not yet exploited with benefits beyond tourism.
The objective of convention promotion is to increase the direct and indirect added value generated by conventions. Additionally, a further strengthening of Basel as the most innovative economic location and center of knowledge in Switzerland is targeted. By promoting conventions, we want to contribute to Basel remaining one of the most important trade fair and convention cities in Europe.
Basel is the most dynamic economic region in Switzerland and one of the most productive and innovative locations worldwide. Basel-Stadt provides employment for about 191,000 people from Switzerland and other countries. Liberal employment laws, attractive corporate tax rates, an efficient public administration and political stability are the traditional strong points which benefit companies in the Basel region.
Basel boasts the highest density of successful life sciences companies in the world. Famous companies such as Novartis, Roche, Lonza, Bayer, BASF, Syngenta or Straumann have their headquarters or important group functions here. A multi-faceted biotope of further research companies from the fields of biotechnology, nanotechnology, IT and communication technology is thriving around them. Together with the University of Basel, the ETH Department of Biosystems and the University of Applied Sciences Northwestern Switzerland FHNW, they form the Life Sciences Cluster. This cluster counts over 700 companies, including big multinationals, SMEs and a constantly growing number of successful start-ups and spin-offs.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular and neuroscience. Through the Bristol Myers Squibb Foundation, an independent 501(c)(3) charitable organization, we support community-based programs that promote cancer awareness, screening, care and support among high-risk populations in the United States, as well as China, Brazil and sub-Saharan Africa. Our employees around the world work every day to transform patients’ lives through science.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Euronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €4.5 trillion in market capitalisation as of end December 2019, Euronext has an unmatched blue chip franchise that includes 26 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. The Norwegian stock exchange and its clearing & settlement subsidiary, together operating as Oslo Børs VPS, joined Euronext on 17 June 2019. For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
Latham & Watkins is one of the largest law firms in the world with more than 2,700 lawyers located in major financial, business and regulatory centers around the globe. Our award-winning Healthcare and Life Sciences practice guides clients through their most significant and cutting-edge legal challenges through a combination of in-depth industry knowledge, legal acumen and strategic business advice. We understand the unique economic, market, regulatory and political climates in which healthcare and life sciences companies operate.
Digital transformation of healthcare and life sciences looks to personalize the patient health journey, improve data-driven decision making, and accelerate precision medicine. Amazon Web Services (AWS) makes this possible with the most comprehensive cloud platform on which healthcare and life science organizations can innovate. With over 100 HIPAA-eligible services, advanced machine learning and analytics tools that are simple to build and deploy, and data interoperability frameworks, healthcare and life science organizations can leverage AWS to speed the development of new therapies, personalize the patient experience, and improve health outcomes.
We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and BeNeLux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technologies. We can invest up to CHF 10 million over the life time of a given portfolio company. BioMedPartners often plays the lead or co-lead investor role, structuring the transaction and syndicating with other venture capital firms. Currently, BioMedPartners manages three investment vehicles, BioMedInvest I (with BioMedCredit), BioMedInvest II and BioMedInvest III with a total capital under management of CHF 350 million. The funds invest in innovative early- to mid-stage companies that have the potential to achieve exceptional growth driven by novel technologies, products or services with unique advantages over current treatments and that are backed by compelling science.
Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Syneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial and consulting, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum.
We are uniquely positioned to bring into sharp focus the issues that matter most to biotech companies and investors through the breadth and depth of our network, and access to the expertise that the wider Syneos Health organization offers.
At Syneos Health, clinical, commercial and consulting live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.